---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-25-002559"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:31:07.588777+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Silexion reports new preclinical data: up to 97% cancer cell inhibition, first evidence against KRAS Q61H mutation

## Summary
- SIL204 achieved up to 97% inhibition in pancreatic cancer cells with KRAS Q61H mutation (previously untested).
- Dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutation at nanomolar concentrations.
- Nearly 90% inhibition in colorectal cancer cells with KRAS G12D mutation, extending efficacy beyond pancreatic cancer.
- Data covers three major KRAS-driven cancers: pancreatic, colorectal, and lung; on track for Phase 2/3 trial in Q2 2026.

## SEC filing metadata
- accession: 0001178913-25-002559
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002559/0001178913-25-002559-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891325002559/zk2533519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-25-002559
- JSON: https://secwatch.observer/filing/0001178913-25-002559.json
- Plain text: https://secwatch.observer/filing/0001178913-25-002559.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.